Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 3/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8431022 | 0.98 | TSHR (0.33) | ADORA2BPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL8062504 | 0.98 | TSHR (0.33) | ADORA2BPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL8952385 | 0.80 | MGLL (0.41) | CYP3A4TSHRLMNA | |
| SCHEMBL8431320 | 0.80 | MGLL (0.41) | CYP3A4TSHRLMNA | |
| SCHEMBL9242254 | 0.80 | ALDH1A1 (0.42) | ADORA2BCYP3A4TSHRLMNA | |
| SCHEMBL15166980 | 0.78 | KDM4E (0.32) | — | |
| SCHEMBL8070808 | 0.77 | KDM4E (0.39) | TSHRLMNA | |
| SCHEMBL7605770 | 0.77 | KDM4E (0.39) | TSHRLMNA | |
| SCHEMBL13835669 | 0.74 | CYP3A4 (0.48) | ADORA2BPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL9122047 | 0.74 | PDE4A (0.47) | ADORA2BPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0697873-A4 | — | — | 1996-04-03 | — | — | EP | claimed |
| EP-0697873-A1 | OLEFIN-SUBSTITUTED LONG CHAIN COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1996-02-28 | — | — | EP | claimed |
| WO-1994015606-A1 | OLEFIN-SUBSTITUTED LONG CHAIN COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-07-21 | — | — | WO | claimed |
| EP-0719267-B1 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS INC (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6121270-A | N-(EPOXYALKYL)XANTHINE DERIVATIVES WHICH MODULATE CELLULAR RESPONSES TO NOXIOUS, PRO-INFLAMMATORY STIMULI | CELL THERAPEUTICS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| US-5866576-A | COMPOUNDS THAT ACT AS DRUGS ON THE CELLULAR AND BIOCHEMICAL LEVEL TO MODULATE CELLULAR RESPONSES TO NOXIOUS, PRO-INFLAMMATORY STIMULI. | CELL THERAPEUTICS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5859017-A | PREVENTING OR TREATING ALLERGIES; INHIBITING INTRACELLULAR GENERATION OF PHOSPHATIDIC ACID AND DIACYLGLYCEROL | CELL THERAPEUTICS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| CN-1040980-C | Second messenger cell signaling inhibitors | CELL THERAPEUTICS INC (US) | 1998-12-02 | — | — | CN | disclosed |
| US-5837703-A | AUTOIMMUNE DISEASES, ARTHRITIS, CANCER, LEUKEMIA, MULTIPLE SCLEROSIS; ANTITUMOR AGENTS | CELL THERAPEUTICS, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5824677-A | SUBSTITUTED WITH HETEROCYCLIC RING, ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE | CELL THERAPEUTICS, INC. (US) | 1998-10-20 | — | — | US | disclosed |
| US-5801181-A | Amino alcohol substituted cyclic compounds | CELL THERAPEUTICS, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| EP-0697873-A1 | OLEFIN-SUBSTITUTED LONG CHAIN COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1996-02-28 | — | — | EP | disclosed |
| EP-0719267-A4 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS INC (US) | 1996-02-16 | — | — | EP | disclosed |
| US-5470878-A | Cell signaling inhibitors | CELL THERAPEUTICS, INC. (US) | 1995-11-28 | — | — | US | disclosed |
| WO-1995026722-A1 | METHOD FOR INHIBITING MAST CELL AND BASOPHIL ACTIVATION | CELL THERAPEUTICS, INC. (US) | 1995-10-12 | — | — | WO | disclosed |
| EP-0662834-A1 | NOVEL EPOXIDE-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1995-07-19 | — | — | EP | disclosed |
| WO-1994022863-A9 | SECOND MESSENGER CELL SIGNALING INHIBITORS | — | 1994-12-22 | — | — | WO | disclosed |
| WO-1994022863-A1 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994015606-A1 | OLEFIN-SUBSTITUTED LONG CHAIN COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994006431-A1 | NOVEL EPOXIDE-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-03-31 | — | — | WO | disclosed |